Cognite Recognized as a Leader in Industrial Data Management Solutions
16.1.2025 15:59:00 CET | Business Wire | Press release
Independent Research Firm positions Cognite Data Fusion® as a market-leading DataOps and AI platform for enterprise-scale, complex industrial data management projects
Cognite, the global leader in AI for industry, today announced it has been named a Leader in the Verdantix Green Quadrant: Industrial Data Management Solutions 2025 report for providing a market-leading DataOps and AI platform for enterprise-scale, complex Industrial Data Management (IDM) projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114915194/en/
Verdantix Green Quadrant: Industrial Data Management Solutions 2025 (Graphic: Business Wire)
The report recognizes Cognite's platform, Cognite Data Fusion®, for its deeply configurable unstructured and structured industrial data orchestration, fast-paced product development, and world-class offering for complex asset-heavy industrial data and AI projects.
Cognite received a perfect score for its ‘data modeling’ capabilities, the foundational element of Cognite Data Fusion® that enables Cognite customers to adapt to emerging trends and stay ahead in a rapidly evolving technological climate. Additionally, Cognite received perfect scores across 'indirect industrial data acquisition,' 'platform development environment,' and 'platform APIs,' and the highest score for 'unstructured data utilization’ of all data platforms reviewed.
Verdantix also highlighted Cognite Atlas AI™ as an example of innovation in making industrial AI work for practical applications. With its focus on real-world usability, Cognite Atlas AI™ was called out for its ability to streamline agent-driven data retrieval and interpretation, supported by an industrial benchmarking report that helps organizations select the most suitable LLMs for their specific use cases.
“Industrial data management solutions play a critical role in enabling organizations to effectively integrate and leverage their data, particularly as AI becomes increasingly central to industrial operations,” said Joe Lamming, Senior Analyst, Industrial Transformation at Verdantix. “Cognite’s market-leading data modeling capabilities contextualize diverse data types, from structured time series to unstructured documents. We see such capabilities as vital for bridging the gap between raw data and actionable insights and automation. Solutions like those offered by Cognite show how industrial knowledge graphs can ground AI applications in domain-specific, cross-referenced truth, enabling organizations to build useful information systems in complex OT, IT, and ET environments.”
"Data modeling is the cornerstone of Cognite's approach to tackling complex industrial challenges," said Geir Engdahl, Chief Product Officer at Cognite. "Our advanced techniques, including our industrial agent workbench Cognite Atlas AI™, bridge the gap between raw data and actionable insights, making information accessible and meaningful to both humans and AI systems. As generative AI reshapes the industrial landscape, our commitment to robust and flexible data modeling ensures we empower customers with the right foundation for innovative AI-powered solutions tailored to their operational realities."
Cognite Data Fusion® serves as the cornerstone of Cosmo Energy's Digitalization (DX) aspirations," said Noriko Rzonca, Ph.D., Chief Digital Officer Cosmo Energy Holdings. “Generative AI-driven data modeling with Cognite empowers our operations to be safer and more optimized. We are thrilled to see them receive this well-deserved recognition as a leader in Industrial Management Solutions."
Read the full report here: Cognite recognized as a leader in Industrial Data Management solutions
Request a demo of Cognite Data Fusion® and Cognite Atlas AI™ here: cognite.com/request-demo
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
About Verdantix
Verdantix is the essential thought-leader for world-enhancing innovation. We support change-makers with our proprietary data, unique expertise and executive networks. Our impactful analysis is delivered via a digital platform, consulting engagements and in-person events to thousands of decision-makers in more than 100 countries. From offices in London, New York and Boston, the Verdantix research team applies the principles of rigour, accuracy and curiosity to help our globally distributed clients solve their most complex challenges. verdantix.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114915194/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom